PTPRZ1 Inhibits the Cisplatin Resistance of Ovarian Cancer by Regulating PI3K/AKT/mTOR Signal Pathway

Abstract Background: Cisplatin resistance (DDP resistance) is a major cause for poor prognosis of ovarian cancer patients. PTPRZ1 has been proven to participate in the occurrence and development of multiple tumors, including tumor resistance. This study was designed to investigate the roles of PTPRZ1 in DDP-resistant ovarian cancer cells and their possible mechanism.Methods: PTPRZ1 expression in ovarian cancer tissues and normal tissues was analyzed by GEPIA database and verified by qRT-PCR. PTPRZ1 expression in normal ovarian cancer cells and DDP-resistant ovarian cancer cells was also analyzed. Subsequently, qRT-PCR, western blot, MTT experiment and flow cytometry were used to assess the effects of PTPRZ1-PI3K/AKT/mTOR regulating axis on cisplatin resistance of ovarian cancer.Results: PTPRZ1 expression was abnormally low in ovarian cancer tissues, and notably reduced in DDP-resistant ovarian cancer cells. MTT experiment and flow cytometer indicated that overexpression of PTPRZ1 enhanced the cisplatin sensitivity of ovarian cancer cells and promoted the cell apoptosis. The results of mechanism research showed that PTPRZ1 exerted its biological effects possibly through blocking PI3K/AKT/mTOR pathway.Conclusion: PTPRZ1 suppresses the cisplatin resistance of ovarian cancer and induces the cytotoxicity by blocking PI3K/AKT/mTOR pathway.